CN109602736A - A kind of bactericidal agent and its sterilization method - Google Patents
A kind of bactericidal agent and its sterilization method Download PDFInfo
- Publication number
- CN109602736A CN109602736A CN201811522325.0A CN201811522325A CN109602736A CN 109602736 A CN109602736 A CN 109602736A CN 201811522325 A CN201811522325 A CN 201811522325A CN 109602736 A CN109602736 A CN 109602736A
- Authority
- CN
- China
- Prior art keywords
- lipstatin
- legionella pneumophilia
- edetate disodium
- breeding
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses a kind of bactericidal agents for inhibiting legionella pneumophilia growth and breeding, including following ingredients: Lipstatin, EDETATE DISODIUM, sodium chloride and pure water；Lipstatin, EDETATE DISODIUM, sodium hypochlorite mass fraction be respectively: 10-15%, 3-10%, 3-10%.The present invention provides a kind of bactericidal agents and its sterilization method for inhibiting legionella pneumophilia growth and breeding, especially for the patient for having infected legionella pneumophilia, when medical pathogen can be flowed down on relevant medical apparatus, and conventional disinfectant and sterilization method, it is unobvious to the Disinfection Effect of legionella pneumophilia both for unspecific bacterium.Bactericidal agent of the invention has very good effect to the growth and breeding for inhibiting legionella pneumophilia.
Description
Technical field
The present invention relates to a kind of bactericidal agent and its sterilization methods, especially a kind of to inhibit going out for legionella pneumophilia growth and breeding
Microbial inoculum.
Background technique
Legionella pneumophilia is a kind of amphitrichous, Gram-negative, the short and small coccobacillus of Legionnella multiform state property.1976
Acute febrile respiratory disease was once broken out in the legion member of U.S. Philadelphia, was studied, finds a kind of bacterium name
For legionella pneumophilia, also known as " veteran bacillus ".Legionella pneumophilia is a kind of water pathogenic bacteria, is primarily present and warm tide
Wet natural environment, it is widely distributed in artificial water application's system, it is the main pathogenic bacteria for causing légionaires' disease.
Legionella pneumophilia is hidden in air conditioner water, once air-conditioning ventilation system mismanagement, can cause human body infection with legionella.
The germ general patient stronger to the people of health and immunity threatens less, can mainly cause gerontal patient, patient with severe symptoms, exempt from
The secondary infection of the low patient of epidemic disease power.Similar to pneumonia, low-grade infection can cause the symptom of some similar common colds for clinical manifestation,
Severe infection then causes pneumonia to merge systemic toxemia synptom, and serious person can lead to death.Legionella is often with air conditioner refrigerating
It is blown out in device with cold wind, causes air pollution, then the aerosol in air containing Legionella is inhaled into people's intrapulmonary through respiratory tract, draw
Pulmonary infection is played, the symptom of the infection of the upper respiratory tract and fever occurs in the infected, and serious person can lead to respiratory failure and kidney failure.Mesh
Before there is no the report of interpersonal direct contact infection légionaires' disease.
Legionella pneumophilia and other Legionnellas are the encountered pathogenic bacteria for curing Hospital-acquired pneumonia, it was reported that legionella pneumophilia
The disease incidence of pneumonia accounts for the 3%~10% of hospital acquired pneumonia, can be caused after openheart surgery osteomyelitis of sternum, pericarditis and
Infection caused by endocarditis and the infection of other surgical incisions and intramuscular injection.Therefore, the units such as hospital are needed to phase
The Medical instruments Appliances of pass carry out radicidation, especially after carrying out diagnosis and treatment to the patient for having infected legionella pneumophilia,
Relevant non-disposable apparatus must carry out the sterilization operation of legionella pneumophilia.
Summary of the invention
The technical problems to be solved by the present invention are: providing a kind of bactericidal agent and its sterilization method.
In order to solve the above technical problems, the technical solution adopted by the present invention is that:
The bactericidal agent for inhibiting legionella pneumophilia growth and breeding, main component can be significantly inhibited present invention firstly provides one kind
It is Lipstatin.
Lipstatin is by the metabolite of the fermented generation of Streptomyces toxytricini, and four hydroperoxide derivatives are Ao Lisi
He, is a kind of slimming drugs (Xenical).
For applicant in practicing process of scientific research, discovery Streptomyces toxytricini can inhibit the growth and breeding of legionella pneumophilia,
Further study show that the metabolite Lipstatin of the fermented generation of Streptomyces toxytricini can significantly inhibit Shi Fei army
Group bacterium.
The present invention provides a kind of bactericidal agent for inhibiting legionella pneumophilia growth and breeding, including following ingredients: Lipstatin,
EDETATE DISODIUM, sodium chloride and pure water；Lipstatin, EDETATE DISODIUM, sodium hypochlorite mass fraction be respectively: 10-
15%、3-10%、3-10%。
Preferably, in the bactericidal agent provided by the invention for inhibiting legionella pneumophilia growth and breeding, Lipstatin, EDTA bis-
The mass fraction of sodium salt, sodium chloride and pure water is respectively: 12%, 8%, 5%.
Using the bactericidal agent, the present invention also provides a kind of sterilization method of the legionella pneumophilia of Medical instruments Appliances,
Include the following steps:
(1) used Medical instruments Appliances are cleaned up, wipes moisture；
(2) configure sterilant solution: sterilant solution includes following ingredients: Lipstatin, EDETATE DISODIUM, sodium chloride and pure
Water purification；Lipstatin, EDETATE DISODIUM, sodium hypochlorite mass fraction be respectively: 10-15%, 3-10%, 3-10%；
(3) medical instrument to be sterilized is put into sterilant solution, impregnates 2-3h；
(4) medical instrument finished will be impregnated to be put into steam sterilization pan, high-temperature sterilization.
Beneficial effects of the present invention:
The present invention provides a kind of bactericidal agents and its sterilization method for inhibiting legionella pneumophilia growth and breeding, especially for infection
The patient of legionella pneumophilia, can flow down when medical pathogen on relevant medical apparatus, and conventional disinfectant and disappear
Malicious method, it is unobvious to the Disinfection Effect of legionella pneumophilia both for unspecific bacterium.Bactericidal agent of the invention is to inhibition
The growth and breeding of legionella pneumophilia has very good effect.
Specific embodiment
Embodiment 1
The present embodiment provides a kind of bactericidal agents for inhibiting legionella pneumophilia growth and breeding, including following ingredients: Lipstatin,
EDETATE DISODIUM, sodium chloride and pure water；Lipstatin, EDETATE DISODIUM, sodium hypochlorite mass fraction be respectively: 15%,
10%、10%。
Embodiment 2
The present embodiment provides a kind of bactericidal agents for inhibiting legionella pneumophilia growth and breeding, including following ingredients: Lipstatin,
EDETATE DISODIUM, sodium chloride and pure water；Lipstatin, EDETATE DISODIUM, sodium hypochlorite mass fraction be respectively: 10%,
3%、3%。
Embodiment 3
In the bactericidal agent provided in this embodiment for inhibiting legionella pneumophilia growth and breeding, Lipstatin, EDETATE DISODIUM, chlorination
The mass fraction of sodium and pure water is respectively: 12%, 8%, 5%.
The fungistatic effect of 4 inhibition zone method of embodiment measurement Lipstatin
(1) bacteriostatic agent configures: the Lipstatin bacteriostatic solution for being 1,5,10,15% with pure water configuration quality score,
(2) plating medium: 10 g/L of peptone, yeast powder 5 g/L, NaCL10 g/L, 20 g/L of agar powder.
(3) method:
The activation of strain and the preparation of bacterium solution: by the legionella pneumophilia strain streak inoculation of freezen protective to plating medium, 37
DEG C culture 24 h；Choose single colonie and be seeded to 100 mL fluid nutrient mediums, 37 DEG C, 200 r/min shaking table cultures stay overnight, bacterium solution is standby
With.
Bacterial strain comes from Qingdao disease prevention and control center.
The preparation of test panel:
Pre-add bacterium solution pour plate method: injecting a certain amount of bacterium solution into the plating medium for having cooled to 50 DEG C or so, mixing
Uniformly, pour plate (about 20 mL/ plate) so that in test panel cell concentration 1 × 10^5-1 × 10^6 CFU/mL it
Between, it is spare after horizontal rest solidification.
Test panel antimicrobial operation: the disk filter paper (diameter 2cm) after sterilizing is put into the antibacterial liquid of different quality containing
In middle dipping a moment, the center for being placed in test panel is taken out, then test panel is put into 37 DEG C of constant incubator and is cultivated
24h。
When antibacterial agent content is certain, the size of inhibition zone has much relations with cell concentration, if cell concentration is excessive,
The effect of meeting antagonism bacteriostatic agent, causes inhibition zone less than normal.Therefore, this experiment is the antibacterial effect of preliminary identification Lipstatin
Fruit,
This experiment simultaneously with pure water as a comparison, verify the fungistatic effect of the Lipstatin solution of different quality containing.Its
The size of inhibition zone is as follows:
| Antibacterial liquid | Pure water | 1 | 5 | 10 | 15 |
| Antibacterial circle diameter (cm) | 0 | 1.3 | 3.5 | 5.1 | 8.7 |
The fungistatic effect of 5 bactericidal agent of embodiment compares
Configuration is by bactericidal agent described in embodiment 1-3, and the bacterium solution cultivated in Example 4 is each by 0.5mL bacterium solution and 4.5mL
Bactericidal agent mixes 10min, then takes every kind of experiment bacterium solution 1mL and the sterile saline mixed diluting of 9 mL is added, take 1 mL
Mixed diluting bacterium solution be inoculated in plating medium, set in constant incubator 37 DEG C of cultures for 24 hours, count total plate count, calculate
Sterilizing rate.
Above-mentioned experimental setup control group selects sterile saline.
As a result as follows:
In the plating medium of control group, bacterium colony is covered with, in the processed bacterium solution of embodiment 1-3 bactericidal agent, in plating medium
Sterile length of being born.
Claims (2)
1. a kind of bactericidal agent for inhibiting legionella pneumophilia growth and breeding, which is characterized in that including following ingredients: Lipstatin,
EDETATE DISODIUM, sodium chloride and pure water；Lipstatin, EDETATE DISODIUM, sodium hypochlorite mass fraction be respectively: 10-
15%、3-10%、3-10%。
2. a kind of sterilization method of the legionella pneumophilia of Medical instruments Appliances, characterized in that it comprises the following steps:
(1) used Medical instruments Appliances are cleaned up, wipes moisture；
(2) configure sterilant solution: sterilant solution includes following ingredients: Lipstatin, EDETATE DISODIUM, sodium chloride and pure
Water purification；Lipstatin, EDETATE DISODIUM, sodium hypochlorite mass fraction be respectively: 10-15%, 3-10%, 3-10%；
(3) medical instrument to be sterilized is put into sterilant solution, impregnates 2-3h；
(4) medical instrument finished will be impregnated to be put into steam sterilization pan, high-temperature sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811522325.0A CN109602736A (en) | 2018-12-13 | 2018-12-13 | A kind of bactericidal agent and its sterilization method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811522325.0A CN109602736A (en) | 2018-12-13 | 2018-12-13 | A kind of bactericidal agent and its sterilization method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109602736A true CN109602736A (en) | 2019-04-12 |
Family
ID=66008294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811522325.0A Pending CN109602736A (en) | 2018-12-13 | 2018-12-13 | A kind of bactericidal agent and its sterilization method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109602736A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111838175A (en) * | 2020-07-23 | 2020-10-30 | 河南李济堂医药科技有限公司 | Safe and non-irritant oral disinfectant formula and production process thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101885713A (en) * | 2010-07-19 | 2010-11-17 | 大邦(湖南)生物制药有限公司 | New process for separating and extracting lipstatin from stretomyces toxytricini fermentation liquor |
| US20110196027A1 (en) * | 2008-02-26 | 2011-08-11 | Ludwig-Maximilians-Universitat Munchen | Beta-lactones as antibacterial agents |
| CN102655745A (en) * | 2009-11-12 | 2012-09-05 | 西格纳姆生物科学公司 | Use of anti-bacterial agents for the treatment of epithelial-related conditions |
| CN103420953A (en) * | 2013-07-19 | 2013-12-04 | 杭州华东医药集团生物工程研究所有限公司 | Method for purifying orlistat intermediate |
| CN103992297A (en) * | 2014-06-06 | 2014-08-20 | 鲁南新时代生物技术有限公司 | Preparation method of lipstatin |
-
2018
- 2018-12-13 CN CN201811522325.0A patent/CN109602736A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110196027A1 (en) * | 2008-02-26 | 2011-08-11 | Ludwig-Maximilians-Universitat Munchen | Beta-lactones as antibacterial agents |
| CN102655745A (en) * | 2009-11-12 | 2012-09-05 | 西格纳姆生物科学公司 | Use of anti-bacterial agents for the treatment of epithelial-related conditions |
| CN101885713A (en) * | 2010-07-19 | 2010-11-17 | 大邦(湖南)生物制药有限公司 | New process for separating and extracting lipstatin from stretomyces toxytricini fermentation liquor |
| CN103420953A (en) * | 2013-07-19 | 2013-12-04 | 杭州华东医药集团生物工程研究所有限公司 | Method for purifying orlistat intermediate |
| CN103992297A (en) * | 2014-06-06 | 2014-08-20 | 鲁南新时代生物技术有限公司 | Preparation method of lipstatin |
Non-Patent Citations (1)
| Title |
|---|
| 李培新: "《医院感染管理手册》", 31 May 2013 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111838175A (en) * | 2020-07-23 | 2020-10-30 | 河南李济堂医药科技有限公司 | Safe and non-irritant oral disinfectant formula and production process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102481383B (en) | To sterilize with oxygen/ozone mixture the method and system in health care place | |
| CN110438091A (en) | One plant of new Friedlander's bacillus bacteriophage and its application | |
| CN102389743A (en) | Formula of medical bacteriostatic humidifying solution | |
| CN104958830B (en) | A kind of anti-infective therapy of subacidity electrolyzed oxidizing water gynaecology equipment | |
| CN110129283A (en) | A kind of short-tail coliphage and its application | |
| JP2016165431A (en) | Wipe-cleaning disinfection sheet | |
| Ahn et al. | Effects of extended storage of chlorhexidine gluconate and benzalkonium chloride solutions on the viability of Burkholderia cenocepacia | |
| CN101658705B (en) | Medical humidification fluid with bacteria resistance function | |
| CN105963680A (en) | Inhibitor used for inhibiting/disintegrating biofilm and application thereof | |
| Pandit et al. | Risk of cross-infection from inhalation anaesthetic equipment | |
| CN109602736A (en) | A kind of bactericidal agent and its sterilization method | |
| Heal et al. | Bacterial contamination of surgical gloves by water droplets spilt after scrubbing | |
| CN113995744A (en) | Composition and antibacterial application thereof | |
| CN103858946B (en) | Spray for disinfecting operation room before operation as well as preparation method and using method thereof | |
| CN108853358A (en) | A kind of antibacterial Chinese medicine composition and its preparation method and application | |
| CN109453163A (en) | A kind of bactericidal agent inhibiting legionella pneumophilia growth and breeding | |
| CN104094979B (en) | Application of the Folium Salicis Babylonicae in disinfectant is prepared | |
| CN102941034A (en) | Medical humidification liquid having bacteriostasis function | |
| Pekovic et al. | Efficacy of ozone gas against mumps virus under experimental environment conditions | |
| CN104000767B (en) | A kind of Feminine care solution and preparation method thereof | |
| CN113647406A (en) | Solid mosquito-repellent incense and preparation method thereof | |
| Pendleton et al. | Bacterial colonisation of humidifier attachments on oxygen concentrators prescribed for long term oxygen therapy: a district review. | |
| CN111202101A (en) | Anti-fogging disposable mask preparation liquid and preparation method thereof | |
| CN106924795B (en) | Hospital environment sterilization purification system | |
| CN106619712A (en) | Application of copper oxide-platinum nanocomposite in antibiosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190412 |